Search
Pyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Nadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and
Hyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.
2-deoxyglucose
go.drugbank.com/drugs/DB08831InvestigationalAs an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. … Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent.
L-tartaric acid
go.drugbank.com/drugs/DB09459ApprovedTartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics
Mixtures: E-Z-gas 2 GranulesSipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigational[L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418]
Tetracosactide
go.drugbank.com/drugs/DB01284ApprovedInvestigationalACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. … The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. … Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology
Tenocyclidine
go.drugbank.com/drugs/DB01520IllicitInvestigationalIt is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Categories: Compounds used in a research, industrial, or household settingAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[L7489] Atezolizumab was granted FDA approval on 18 October 2016. … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.